Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cholesterol lowering and life expectancy: a critical evaluation].

H Klepzig1, M Kaltenbach

  • 1Abteilung für Kardiologie Zentrums der Inneren Medizin Klinikums der Johann-Wolfgang-Goethe-Universität, Frankfurt, Main.

Zeitschrift Fur Kardiologie
|July 11, 1992
PubMed
Summary

Lowering serum cholesterol reduces coronary events by 2% per 1% reduction. However, this therapy has not been proven to increase life expectancy, with some studies showing increased extracardiac mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angina pectoris in consequence of subtotal subclavian artery stenosis 2 years after CABG.

The Thoracic and cardiovascular surgeon·2010
Same author

[Familial Mediterranean fever (familial paraoxysmal polyserositis)].

Deutsche medizinische Wochenschrift (1946)·2003
Same author

Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic.

International journal of clinical pharmacology and therapeutics·2002
Same author

Effect of atenolol and celiprolol on acetylcholine-induced coronary vasomotion in coronary artery disease.

The American journal of cardiology·2000
Same author

[Clinic internal hypertext information system].

Deutsche medizinische Wochenschrift (1946)·1999
Same author

[Determinants of treatment costs of unstable angina pectoris].

Zeitschrift fur Kardiologie·1999

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Public Health

Context:

  • Established positive correlation between elevated serum cholesterol and coronary artery disease (CAD).
  • Cholesterol-lowering interventions aim to mitigate cardiovascular risk.
  • Understanding the net benefit of cholesterol reduction on overall mortality is crucial.

Purpose:

  • To evaluate the impact of cholesterol-lowering therapy on coronary events and overall life expectancy.
  • To analyze the efficacy of cholesterol reduction in modifying coronary plaque burden.
  • To assess the safety profile, including extracardiac mortality, of cholesterol-lowering treatments.

Summary:

  • A 1% reduction in serum cholesterol correlates with a 2% decrease in coronary events.
  • Cholesterol-lowering therapy shows minimal impact on coronary lesion reduction, likely due to low lipid content in plaques (5-15%).

Related Experiment Videos

  • Intervention trials frequently report an increase in extracardiac mortality.

    • Impact:

    • Current evidence does not conclusively demonstrate that cholesterol-lowering therapy increases life expectancy.
    • The observed increase in extracardiac mortality warrants further investigation into the overall risk-benefit ratio.
    • Findings suggest a need for re-evaluation of long-term therapeutic goals and strategies in cardiovascular disease management.